SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+0.83%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.45B
AUM Growth
+$1.45B
(+14%)
Cap. Flow
+$220M
Cap. Flow
% of AUM
15.19%
Top 10 Holdings %
Top 10 Hldgs %
47.24%
Holding
102
New
27
Increased
19
Reduced
27
Closed
7
Top Buys
| 1 |
Krystal Biotech
KRYS
|
$66.1M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$34.8M |
| 3 |
UroGen Pharma
URGN
|
$29.9M |
| 4 |
Elevance Health
ELV
|
$27.2M |
| 5 |
UnitedHealth
UNH
|
$26.9M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$21.7M |
| 2 |
Insmed
INSM
|
$20.3M |
| 3 |
Hologic
HOLX
|
$18.7M |
| 4 |
Merus
MRUS
|
$18.2M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$18M |
Sector Composition
| 1 | Healthcare | 99.87% |
| 2 | Consumer Staples | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Krystal Biotech
KRYS
$4.27B
| $127M | 8.4% | 922,958 +481,200 | +109% | +$66.1M |
|
2
NovoCure
NVCR
$1.38B
| $123M | 8.14% | 6,904,302 +1,382,888 | +25% | +$24.6M |
|
|
3
TG Therapeutics
TGTX
$4.65B
| $80.8M | 5.35% | 2,243,935 -602,768 | -21% | -$21.7M |
|
4
United Therapeutics
UTHR
$13.8B
| $60.3M | 3.99% | 209,794 +54,400 | +35% | +$15.6M |
|
|
BBNX
5
Beta Bionics, Inc. Common Stock
BBNX
$819M
| $55.6M | 3.68% | 3,820,158 +424,817 | +13% | +$6.19M |
|
6
Grifois
GRFS
$6.78B
| $52M | 3.45% | 5,756,805 -1,333,017 | -19% | -$12.1M |
|
7
STAAR Surgical
STAA
$1.36B
| $50.1M | 3.32% | 2,984,733 +421,840 | +16% | +$7.08M |
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $49.6M | 3.28% | 902,304 -177,000 | -16% | -$9.73M |
|
9
Organogenesis Holdings
ORGO
$653M
| $45.2M | 2.99% | 12,343,351 -135,000 | -1% | -$494K |
|
10
Praxis Precision Medicines
PRAX
$958M
| $40.7M | 2.69% | 966,740 -173,000 | -15% | -$7.27M |
|
11
Celcuity
CELC
$2.17B
| $40.2M | 2.66% | 3,011,818 +437,696 | +17% | +$5.84M |
|
|
12
Alnylam Pharmaceuticals
ALNY
$58.5B
| $34.8M | 2.31% | +106,750 | New | +$34.8M |
|
13
Terns Pharmaceuticals
TERN
$609M
| $30.5M | 2.02% | 8,167,100 | – | – |
|
|
14
UroGen Pharma
URGN
$900M
| $29.9M | 1.98% | +2,185,000 | New | +$29.9M |
|
15
Nurix Therapeutics
NRIX
$714M
| $27.6M | 1.83% | 2,422,833 | – | – |
|
|
16
Elevance Health
ELV
$71.8B
| $27.2M | 1.8% | +70,000 | New | +$27.2M |
|
|
17
UnitedHealth
UNH
$281B
| $26.9M | 1.78% | +86,250 | New | +$26.9M |
|
18
Neuropace
NPCE
$303M
| $25.8M | 1.71% | 2,312,957 -295,211 | -11% | -$3.29M |
|
19
argenx
ARGX
$43.6B
| $23.6M | 1.57% | 42,876 +13,936 | +48% | +$7.68M |
|
20
Surmodics
SRDX
$487M
| $23.4M | 1.55% | 789,060 | – | – |
|
21
Geron
GERN
$893M
| $22.8M | 1.51% | 16,140,000 +13,740,000 | +573% | +$19.4M |
|
22
Cidara Therapeutics
CDTX
$1.66B
| $22.5M | 1.49% | +462,811 | New | +$22.5M |
|
23
Evolus
EOLS
$494M
| $19.5M | 1.29% | 2,119,000 +1,039,842 | +96% | +$9.58M |
|
24
Humana
HUM
$36.5B
| $19.5M | 1.29% | +79,600 | New | +$19.5M |
|
25
Veracyte
VCYT
$2.39B
| $19.3M | 1.28% | +715,439 | New | +$19.3M |
|